Pharming Group posted a 30% year-over-year revenue increase to $97.3 million in Q3 2025 and lifted full-year guidance to $365–$375 million. Operating profit rose to $15.8 million, supported by $32 million in operating cash flow for the quarter. Growth was driven by Ruconest in acute hereditary angioedema, up 29% to $82.2 million on U.S. volume, and by Joenja (leniolisib) for APDS, up 35% to $15.1 million. The FDA granted priority review for a supplemental application to extend Joenja to children aged 4–11, with a decision due by January 31, 2026. Pharming also said it will withdraw Ruconest from non-U.S. markets and announced a commercial leadership transition effective January 1, 2026.
The strategic signal is clear: Pharming is focusing on high-yield geographies and precision rare-disease growth while stripping out lower-return complexity. Exiting non-U.S. Ruconest markets—only 1.3% of product revenue—frees resources to defend U.S. HAE share as the first oral on-demand competitor gains traction and to accelerate Joenja’s label expansion and diagnostic activation. The bet is that operational focus and capital redeployment will outpace any reputational or access drag from exiting small ex-U.S. markets.
This matters now because the HAE acute segment is in flux. An oral on-demand therapy launched in July should have eroded IV options. Yet, Ruconest unit volumes rose 24% in the quarter, suggesting pockets of durable preference for reliable, rapid IV control amid a prophylaxis-heavy landscape that reduces attack frequency. For payers, a U.S.-centric Ruconest with growing volumes tightens rebate and contracting dynamics in a shrinking on-demand pool. For competitors, it underscores that convenience does not uniformly displace established efficacy, but the erosion curve could steepen as prescribers become more familiar with oral agents.
In APDS, Pharming is executing the rare disease playbook: expand the label, scale genetic identification, and anchor value with adherence and outcomes. The pediatric priority review and early U.K. uptake are notable. Still, the more consequential lever is the potential reclassification of a subset of more than 1,400 U.S. patients carrying variants of uncertain significance in PIK3CD/PIK3R1. If approximately 20% are reclassified, the eligible U.S. pool could materially expand beyond today’s identified 175 adolescents and adults and 54 children already in the system. Realizing that upside will hinge on Medical Affairs converting academic evidence into lab action and payer-accepted diagnostic standards, coupled with targeted HCP education and RWE to sustain premium pricing.
Pharming’s cost discipline and portfolio posture align with broader mid-cap rare disease trends: U.S.-first monetization, pruning low-margin geographies, intensifying diagnostic activation, and using BD to extend the pipeline. Cash generation, an AMX index promotion, and a new commercial leader with analytics depth position the company to pivot from single-brand dependence toward a two-asset platform while advancing KL1333 in mitochondrial disease and absorbing recent deal costs.
The following 12 months will set up a straightforward test. If the FDA pediatric decision lands on time, lab reclassification proceeds at commercial speed, and U.S. payers align on coverage for newly diagnosed children, Joenja’s revenue slope changes meaningfully. If Ruconest can sustain U.S. growth as oral on-demand options mature, Pharming buys the runway to turn leniolisib from an APDS label into a broader PID franchise. The open question is whether diagnostic and payer execution can move fast enough to offset any medium-term HAE erosion and fund the company’s ambition to be a leading rare disease player.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
